2003-04-25

Cloning and Expression of Plasmids Encoding Multimers of Antimicrobial Peptides Indolicidin and PGQ

Kimberly M. Morin
Worcester Polytechnic Institute

Follow this and additional works at: https://digitalcommons.wpi.edu/etd-theses

Repository Citation
https://digitalcommons.wpi.edu/etd-theses/280

This thesis is brought to you for free and open access by Digital WPI. It has been accepted for inclusion in Masters Theses (All Theses, All Years) by an authorized administrator of Digital WPI. For more information, please contact wpi-etd@wpi.edu.
CLONING AND EXPRESSION OF PLASMIDS ENCODING MULTIMERS OF ANTIMICROBIAL PEPTIDES INDOLICIDIN AND PGQ

A Thesis
Submitted to the faculty of
WORCESTER POLYTECHNIC INSTITUTE
In partial fulfillment of the requirements for the
Degree of Master of Science
In
Biology
By

______________________________
Kimberly M. Morin

04/30/2003

APPROVED:

__________________   __________________   __________________
Charlene Mello, Ph.D.   David S Adams, Ph.D.   Samuel Politz, Ph.D.
Major Advisor     Committee Member    Committee Member
Natick Soldier Systems Center
ABSTRACT

Antimicrobial peptides are active against bacteria, fungi and viruses as part of the innate immune system in animals and insects. Such peptides are currently produced by extracting them from the host organism or by solid phase peptide synthesis; both techniques are expensive and produce low yields. Recombinant DNA technology opens a window to produce these peptides inexpensively and in large quantities utilizing E. coli expression systems. Two antimicrobial peptides, indolicidin and PGQ, were the focus of this work. They are short amphipathic alpha helical antimicrobial peptides that target a broad range of microorganisms. Genes encoding multimers of indolicidin, PGQ and a hybrid of indolicidin:PGQ were placed into protein expression vectors pET32a+ and pET43.1a+, for peptide production in E. coli. A combination of multimerization and the use of a fusion protein were utilized to mask the toxicity of these peptides in E. coli. The multimerized peptide fusion construct was purified using Ni/NTA affinity chromatography. Methionine residues flanking each monomeric unit were utilized to enable cleavage of the multimerized protein and liberating a biologically active peptide. A Trx:indolicidin trimer fusion was produced in the greatest yield of all constructs investigated. Upon cyanogen bromide cleavage, a band corresponding to the theoretical molecular weight of an indolicidin monomer was observed with SDS-PAGE. Antimicrobial activity of monomeric recombinant indolicidin was tested resulting in zones of clearing. Overall the results indicate that multimerizing antimicrobial peptide genes can potentially produce a larger quantity of peptide per bacterial cell. These studies suggest that multimerization of antimicrobial peptide genes represents a means to
control *in vivo* toxicity of the recombinant peptides and increase production relative to single gene fusions.
TABLE OF CONTENTS

ABSTRACT .......................................................................................................................... 2

LIST OF FIGURES AND TABLES. ................................................................................... 5

BACKGROUND ................................................................................................................ 8

MATERIALS AND METHODS ........................................................................................ 25

RESULTS .......................................................................................................................... 41

DISCUSSION .................................................................................................................... 61

BIBLIOGRAPHY ............................................................................................................. 66

APPENDIX 1 VECTOR MAP OF PET28A+ ................................................................. 69

APPENDIX 2 VECTOR MAP OF PET32A+ ................................................................. 70

APPENDIX 3 VECTOR MAP OF PET43.1A+ .............................................................. 71

APPENDIX 4 VECTOR MAP OF PQE-30 ................................................................. 72

APPENDIX 5 VECTOR MAP OF PGEX-4T-2 ............................................................ 73

APPENDIX 6 VECTOR MAP OF PUC18 ................................................................. 74

APPENDIX 7 SEQUENCING RESULTS OF IND3 IN PUC-LINK ............................... 75

APPENDIX 8 SEQUENCING RESULTS OF IND6 IN PUC-LINK ............................... 76

APPENDIX 9 SEQUENCING RESULTS OF IP IN PUC-LINK ...................................... 77

APPENDIX 10 SEQUENCING RESULTS OF (IP)_2 IN PUC-LINK ............................ 78

APPENDIX 11 SEQUENCING RESULTS OF IPP IN PUC-LINK .................................. 79

APPENDIX 12 SEQUENCING RESULTS OF PGQ3 IN PUC-LINK .............................. 80

APPENDIX 13 SEQUENCING RESULTS OF PGQ6 IN PUC-LINK .............................. 81
LIST OF FIGURES AND TABLES

Figure 1 Classification of Antimicrobial Peptides.............................................................. 9
Table 1 Antimicrobial Activity of Indolicidin.................................................................. 11
Figure 2 Gram-Negative Bacterial Cell Wall ................................................................. 13
Figure 3 Gram-Positive Bacterial Cell Membrane ......................................................... 14
Figure 4 Proposed Membrane Permeability Mechanism for α-helical Peptides .......... 15
Table 2 Antimicrobial Peptide Expression Systems used in the Literature................. 19
Figure 5 Multimerization using Nhe I and Spe I Restriction Sites........................................ 22
Figure 6 DNA and Amino Acid Sequence of Indolicidin and PGQ............................. 23
Figure 7 DNA Sequence of Synthetic Adapter Inserted into pUC18 to Create pUC-link 25
Table 3 Expression Vectors Used in this Project.............................................................. 27
Table 4 E. coli Host Strains .............................................................................................. 28
Figure 8 Multimerization of Antimicrobial Peptide Genes ............................................ 41
Figure 9 Determination of Correct Insertion of Multimerized DNA Insert.................... 42
Figure 10 Cloning and Expression of Multimerized Antimicrobial Peptide Genes in E. coli......................................................................................................................... 44
Figure 11 SDS-PAGE Analysis of Cell Lysates............................................................... 45
Figure 12 SDS-PAGE Analysis of Nickel Purified Protein.............................................. 46
Table 5 Vectors and Inserts used for In Vitro Transcription/Translation ....................... 47
Figure 13 In Vitro Transcription/Translation Results.................................................... 48
Figure 14 Expression of Trx:PGQ6 in Various Host Strains............................................ 50
Figure 15 Expression of NusA:PGQ6 in Various Host Strains........................................ 51
Figure 16 Expression of Trx:Ind3 in Various Host Strains ............................................ 52
Figure 17 Expression of Trx:hyb(IP)₂ in Various Host Strains........................................ 53

Figure 18 SDS-PAGE of NusA:PGQ6, Trx:Ind3, Trx:hyb(IP)₂ Cell Lysates and Nickel
     Purified.......................................................................................................................... 54

Figure 19 Cyanogen Bromide Cleavage Site in Multimerized Peptide............................ 55

Figure 20 CNBr Cleavage of Trx:Ind3 ............................................................................. 55

Table 6 Amino Acid Analysis Trx:Ind3 Purified Sample ................................................ 57

Table 7 Quantitation of Indolicidin Monomer............................................................... 58

Figure 21 Plate Overlay of Cyanogen Bromide Digested Trx:Ind3 ............................... 59

Figure 22 Plate Overlay of Cyanogen Bromide Digested Trx fusion protein ............... 60
I would like to thank Dr. Charlene Mello for assistance with designing and executing this project at the Soldier Systems Center. I would also like to thank Steve Arcidiacono for working closely with me, and helping me with day-to-day experiments. I would also like to thank Prof. Richard Beckwitt for all the previous work he did on this project and for teaching me recombinant DNA techniques. Lastly I would like to thank Prof. David Adams and Prof. Samuel Politz for their helpful suggestions and guidance.
Antimicrobial Peptides

History of Antimicrobial Peptides

Small peptides that fight microbial infection are natural antibiotics that function as part of the innate immune system of vertebrates and invertebrates (Sitaram and Nagaraj, 1999). This system, present since birth, attempts to continually keep microbial infection under control. Antimicrobial peptides have been classified based on their tertiary structures into categories such as linear peptides, alpha helical peptides, beta sheet peptides, and single amino acid rich sequence peptides (Figure 1) (Epand and Vogel, 1999). The action of these peptides ranges from physical barriers to cell mediated immune responses to microorganisms (Nicolas and Mor, 1995). Thus far over 100 different antimicrobial peptides have been discovered in vertebrates. These discoveries may help medicine, as many organisms have become resistant to antibiotics currently in use. Many of these peptides are structurally similar to each other and typically range in molecular weight from 1,000-5,000 Da, are polycationic, and span the bacterial membrane.

Classification

There are five main groups of antimicrobial peptides, delineated by structural characteristics (Figure 1). The amphipathic helical peptides were first identified in amphibians and are secreted through the skin. Most consist of linear peptides ranging from 20-36 residues long, which are cationic and have varying numbers of lysine
residues. Their activity is stimulated by cationic binding to membranes as a result of α-helical formation in an anisotropic environment (Spencer, 1992). There are also α-helical peptides, which are hydrophobic and slightly anionic (Epand and Vogel, 1999).

**Classification of Antimicrobial Peptides**

<table>
<thead>
<tr>
<th>Amphipathic and hydrophobic helices</th>
<th>Cyclic peptides and β-sheet structures</th>
<th>Peptides with irregular amino acid composition</th>
<th>Peptides with thioester rings</th>
<th>Peptaibols</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magainin</td>
<td>Tachyplesins, protegrins, defensins</td>
<td>Indolicidin, tritpticin, PR-39, prophenin</td>
<td>Lantibiotics</td>
<td>Trichogin, alamethicin</td>
</tr>
<tr>
<td>PGQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Figure 1 Classification of Antimicrobial Peptides*

The classification of antimicrobial peptides, which is determined based on structure of each peptide group. Indolicidin and PGQ are highlighted because these are the peptides used for this project.

Trisulfide-rich peptides, such as defensins and β-defensins, range from 29-42 amino acid residues long (Lehrer et al, 1993) and belong to the class of β-sheet and cyclic peptides. These Arg-rich peptides play an important role in the nonoxidative microbicidal mechanism in which cells produce intracellular phagocytotic vacuoles, which ingest microorganisms (Selsted et al, 1993). Both defensins and β-defensins exhibit a broad range of activity against gram-positive and gram-negative bacteria, mycobacteria, spirochetes, fungi and enveloped viruses. The main distinguishing factor of the defensin family is a triple stranded anti-parallel β-sheet interconnected with disulfide bonds (Nicolas and Mor, 1995).
Some antimicrobial peptides are characterized by an unusually high abundance of one or two amino acids. Indolicidin and tritrypticin contain large numbers of tryptophan residues; tryptophan is generally not an abundant amino acid in peptides or proteins (Epand and Vogel, 1999). The proline and arginine-rich antimicrobial peptides are composed of more than 60% pro and arg collectively. They have highly repetitive sequences (eg. Arg-Pro-Pro or Pro-Arg-Pro), and are mainly active against gram-negative bacteria (Agerberth et al, 1991).

Peptides with thio-ester rings, also referred to as lantibiotics, are produced by bacteria and contain small ring structures enclosed by a thio-ester bond (Epand and Vogel, 1999). Finally, peptailbols contain a high number of α-amino-isobutyric acid residues. This enables the peptides to form a α-helical structure in a particular conformation. These peptides are also acylated at the N-terminus, which favors their insertion into membranes (Epand and Vogel, 1999).

The antimicrobial peptides indolicidin and PGQ (highlighted in red in Figure 1) are the main focus of this thesis. They were chosen due to their activity against microbes cultured from a sample of solid waste for which the expression of these peptides is targeted. A library of antimicrobial peptides was tested for activity against this solid waste sample, and indolicidin and PGQ demonstrated the best antimicrobial activity (Mello, unpublished).

*Indolicidin*

Indolicidin was first discovered in the cytoplasmic granules of bovine neutrophils (Falla et al, 1996). It belongs to the cathelicidin family of proteins, which are
distinguished by variable C-termini and common amino acid structure (Sitaram and Nagaraj, 1999).

The smallest of all naturally occurring linear antimicrobial peptides, indolicidin is only 13 amino acids long. Its unique shape, not belonging to either the alpha helix or beta sheet family, is a result of its primary structure, consisting of 39% tryptophan and 23% proline (Falla et al, 1996). It also contains only 6 different amino acids and is amidated at the carboxyl terminus in nature. Indolicidin is active against gram-negative and gram-positive bacteria as well as fungi and protozoa. Natural indolicidin is active in small (µg/ml) quantities against the organisms listed in Table 1. It also exhibits antiviral

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>MIC (µg/ml)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W 160 37</td>
<td>25</td>
<td>(Subbalakshmi et al, 1996)</td>
</tr>
<tr>
<td>ML35</td>
<td>10</td>
<td>(Selsted et al, 1992)</td>
</tr>
<tr>
<td>UB1005</td>
<td>16</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>DC2</td>
<td>4</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>DH5α</td>
<td>28</td>
<td>(Staubitz et al, 2001)</td>
</tr>
<tr>
<td><em>S. aureus</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATCC 8530</td>
<td>4</td>
<td>(Subbalakshmi et al, 1996)</td>
</tr>
<tr>
<td>502A</td>
<td>10</td>
<td>(Selsted et al, 1992)</td>
</tr>
<tr>
<td>ATCC 25923</td>
<td>8</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>Newman</td>
<td>12</td>
<td>(Staubitz et al, 2001)</td>
</tr>
<tr>
<td>RN4220</td>
<td>8</td>
<td>(Falla et al, 1996)</td>
</tr>
<tr>
<td><em>S. cerevisiae</em> PEP 43</td>
<td>25</td>
<td>(Subbalakshmi et al, 1996)</td>
</tr>
<tr>
<td><em>C. utilis</em> CBS 4511</td>
<td>25</td>
<td>(Subbalakshmi et al, 1996)</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H103</td>
<td>64</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>K799</td>
<td>64</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>Z61</td>
<td>4</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td><em>S. typhimurium</em></td>
<td>64</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>14028s</td>
<td>64</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td>MS7953a</td>
<td>8</td>
<td>(Falla et al, 1997)</td>
</tr>
<tr>
<td><em>S. epidermidis</em> C621</td>
<td>4</td>
<td>(Falla et al, 1997)</td>
</tr>
</tbody>
</table>

MIC = minimum inhibitory concentration

Table 1 Antimicrobial Activity of Indolicidin
activity against HIV-1 (Sitaram and Nagaraj, 1999). Unfortunately, it is cytotoxic to rat and human T lymphocytes, and lyses red blood cells (Falla et al, 1996), but may have practical applications in textiles for biological agent decontamination. Indolicidin has been shown to inhibit DNA synthesis through penetration into the cytoplasmic membrane (Subbalakshmi and Sitaram, 1998). Lysis of the bacteria does not occur, but rather filamentation of the cells and blockage of replication occurs due to the blockage of thymidine incorporation.

PGQ

PGQ stands for peptide with an amino-terminal glycine and carboxyl-terminal glutamine and comes from the African clawed frog *Xenopus laevis* (Moore et al, 1991). It is in the group of antimicrobial peptides called magainins, a sub-class of amphipathic α-helical peptides, which are secreted from the skin of *Xenopus laevis*. All peptides in the magainin family range from 21-26 amino acids long and are lysine rich basic proteins (Moore et al, 1991). They are released from the frog upon injury or adrenergic stimulation to battle against gram-negative and gram-positive bacteria, fungi and protozoa. These and other peptides are stored in the skin in large granules. The stomach of *Xenopus laevis* also contains many antimicrobial peptides, including PGQ. Within the stomach, PGQ is stored in the granular multinucleated cells in the gastric mucosa.
Mechanism of Action

Many mechanisms of action have been proposed for antimicrobial peptides. One mechanism of \(\alpha\)-helical and \(\beta\)-sheet peptides is targeted towards the lipid bilayer of the bacteria by use of self-promoted uptake where the peptide embeds itself within the lipid bilayer forming a channel (Falla et al, 1996). This increases the rate of leakage of the cytoplasmic membrane of gram-negative and gram-positive cells (Figures 2 and 3) through cationic binding to the negatively charged lipid membrane (Figure 4) (Epand and Vogel, 1999). This binding is achieved during tertiary folding of the peptides upon association with the bacterial cell membrane (Hancock and Rozek, 2002). For many peptides, excluding indolicidin, this inhibits their toxicity to eukaryotic neutrally

Figure 2 Gram-Negative Bacterial Cell Wall
This represents the composition of a gram-negative bacteria cell wall including the cell membrane. This differentiates from the gram-positive cell membrane, because it contains a cell wall (shown in green).
http://www.bact.wisc.edu/microtextbook/bacterialstructure/CellWall.html
charged cell membranes (Huang et al, 2000). Indolicidin has the ability to break through the lipid bilayer by cationic binding, but exerts its activity by inhibition of DNA synthesis (Subbalakshmi and Sitaram, 1998). Direct interaction with the lipid bilayer was hypothesized after replacing L-amino acids with all D enantiomers. This did not inhibit membrane binding due to stereospecific protein receptors as previously thought (Huang et al, 2000). Several peptides can influence molecular synthesis at concentrations that do not cause the breakdown of the membrane potential, suggesting that other mechanisms are important in addition to effects on membrane permeability. Activity of the proline-arginine rich peptide PR-39 leads to inhibition of protein synthesis and induction of degradation of proteins required for DNA replication (Ramanthan et al, 2002). Other peptides have clearly been shown to permeabilize the membrane and cause cytoplasmic leakage (Hancock and Rozek, 2002). Several cathelicidins have been shown to decrease
bacterial respiration, caused by deterioration of the inner membrane (Ramanathan et al, 2002).

![Figure 4 Proposed Membrane Permeability Mechanism for α-helical Peptides](image)

**Figure 4 Proposed Membrane Permeability Mechanism for α-helical Peptides**

This mechanism of action of antimicrobial peptides involves the permeation of the lipid bilayer. This is achieved when the cationic peptide interacts with the anionic phospholipid bilayer. The peptide then forms a pore with multiple peptides and thus enters the cell (Epand and Vogel, 1999).

**Potential Applications**

Antimicrobial peptides are now being investigated by many pharmaceutical companies for their wide range of activity against many bacteria and fungi. Due to an increase in bacterial resistance to many antibiotics, antimicrobial peptides are a promising approach in the development of new drugs (Hancock and Rozek, 2002). A potentially important feature is their low probability of selecting for resistance in target microbes because they have evolved as part of innate immune responses. Antimicrobial peptides bind and kill bacteria, fungi and viruses; this may be useful in biological decontamination and preservation of food products. A major challenge is production of these small peptides in commercial quantities. For production of these peptides to be valuable in industry, they must be produced in an environmentally safe and cost effective manner.
Current Methods of Production

As mentioned above, these peptides were discovered in invertebrates and vertebrates as part of the innate immune system. For years they have been extracted from eukaryotic tissue to test their mechanism of action and classify the peptides. This requires tissue extraction or eukaryotic cell expression, which produces low yields of protein. Solid phase peptide synthesis is currently used to produce natural peptide sequences, as well as variations, to create novel antimicrobial peptides. This procedure requires hazardous chemicals and costly reagents. In contrast, recombinant DNA technology has been used to clone natural or synthetic genes in bacteria, fungi, plants, or yeast cells for increased production of many eukaryotic and prokaryotic proteins.

Many different host/vector systems have been used to produce antimicrobial peptides through recombinant DNA technology. *E. coli* has been utilized most often due to the low cost of fermentation compared to mammalian cells, and its ability to produce inclusion bodies, which aid in the purification process (Haught et al, 1998). The main source of success in *E. coli* expression of antimicrobial peptides has been through the use of fusion proteins, which are large proteins composed of an unrelated protein fused to the protein of interest (Hara and Yamakawa, 1996). This aids expression by alleviating the toxicity and proteolytic degradation of the expressed antimicrobial peptide.

Review of Published Expression Studies

As mentioned previously, antimicrobial peptides are now being looked at to combat antibiotic resistant strains of bacteria. Since this is very important in the medical
field, many scientists are trying to produce these short peptides using bacterial systems. Antimicrobial peptides have been successfully expressed using several different methods, including commercially available fusion proteins (Piers et al, 1993), N-terminal inclusion body forming proteins (Haught et al, 1998; Lee et al, 2000), an N-terminal anionic pre-pro region (Zhang et al, 1998), and tandem repeats of an anionic complement and antimicrobial peptide (Lee et al, 1998).

These different methods of gene arrangement of the antimicrobial peptides were resorted to because of the expression problems that arose during experimentation. Fusion proteins were chosen based on natural proteins or portions of natural proteins that enhance the formation of inclusion bodies to aid in purification as well as result in the reduction of proteolytic degradation (Piers et al, 1993; Taguchi et al, 1994; Lee et al, 1998). Piers et al. (1993) used OprF, an outer membrane protein in P. aeruginosa, along with pre-pro defensin to inhibit proteolytic degradation and induce formation of inclusion bodies. Lee et al. (1998) fused buforin II to an acidic positively charged peptide to mimic the natural precursor of buforin II. The gene encoding this anionic/cationic peptide complex was then multimerized and expressed at a yield of 107 mg/L active peptide. Ponti et al. (1999) used a C-terminal fusion of GABA-transaminase to produce inclusion bodies and decrease proteolytic degradation. Haught et al. (1998) utilized bovine prochymosin to decrease toxicity of the antimicrobial peptide and induce inclusion bodies. Zhang et al. (1998) experimented with different combinations of an anionic stabilizing fragment and an anionic pre-pro sequence (HNP-1) to successfully express several antimicrobial peptides including indolicidin.
There are hundreds of different antimicrobial peptides and each one may be active in different ways against different microorganisms. Only a few peptides have been produced using recombinant DNA techniques (Table 2) including cecropin A (Andersons et al, 1991; Hellers et al, 1991); defensin A (Reichhart et al, 1992); CEME, a cecropin-melittin hybrid (Piers et al, 1993); apidaecin (Taguchi et al, 1994); moricin (Hara et al, 1996); magainin P2 (Haught et al, 1998); buforin II (Lee et al, 1998); bactenecin and indolicidin (Zhang et al, 1998); esculentin-1 (Ponti et al, 1999); MiAMP1 (Harrison et al, 1999); and MSI-344 (Lee et al, 2000). PGQ has not been produced recombinantly, and as mentioned above, shows activity in a wide range of microorganisms.

Although it has been proven that antimicrobial peptides can be produced in vivo, it is unclear if they can be produced in large quantities due to their toxicity to the host organism. Yield of active protein produced by various expression systems varies due to the variety of methods for protein expression and purification. The purified active peptide concentration of esculentin-GABA-T (Ponti et al, 1999) and MetP2 (Haught et al, 1998) was 0.5-1 mg/L. This fusion protein was produced in a 1 L shake flask culture and inclusion bodies purified by RP-HPLC. MSI-344 (Hwang et al, 2001) expressed 310 mg/L of active purified peptide using a 1 L fermentor grown to a high cell density before induction, followed by 12 hours of growth after induction. MMIS-Buforin II (Lee et al, 1998) was expressed at 107 mg/L of purified buforin II using a 30 L fermentor and a high cell density and long induction time. These variations in peptide expression and purification make methods direct comparisons of expression systems impossible.
Table 2 Antimicrobial Peptide Expression Systems used in the Literature

<table>
<thead>
<tr>
<th>Recombinant Peptide</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met fXa Met</td>
<td>•Used commercial PGEX •Reduced degradation</td>
<td>•Needed to add pre-pro defensin for expression •Used S. aureus for expression</td>
<td>Piers et al., 1993</td>
</tr>
<tr>
<td>MMIS</td>
<td>Buforin II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydroxylamine Cleavage</td>
<td>•Multiple peptide genes used •F4 fusion reinforces inclusion bodies</td>
<td>•No yield stated, assumed low •Plasmid not commercially available</td>
<td>Hwang et al. 2001</td>
</tr>
<tr>
<td>Rep21 CBD Pre/Pro AMP</td>
<td>•Multiple peptide genes used</td>
<td>•Multiple fusion proteins needed</td>
<td>Zhang et al. 1998</td>
</tr>
<tr>
<td>Met Prochymosin P2</td>
<td>•Fusion protein reinforces inclusion body formation •Simple design</td>
<td>•Low peptide yield</td>
<td>Haught et al. 1998</td>
</tr>
<tr>
<td>Hydroxylamine Cleavage</td>
<td>•Large expression yield •Simple design</td>
<td>•Plasmid not commercially available</td>
<td>Lee et al. 2000</td>
</tr>
<tr>
<td>Rep21 CBD Pre/Pro AMP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Met Esculentin</td>
<td>GABA-T</td>
<td>•Utilized C-terminal fusion instead of N-terminal fusion like all other papers •Commerially available vector</td>
<td>•Low peptide yield</td>
</tr>
</tbody>
</table>

Although different fusion proteins and expression vectors were used in all of these studies, there were many similarities in the expression and purification procedures. All used *E. coli* cells with a lac promoter, and induced expression with isopropyl β-D-1-thiogalactopyranoside (IPTG). The construction of the protein complexes included flanking methionine residues to allow release of the antimicrobial peptide by cyanogen bromide (CNBr) cleavage of the fusion protein. CNBr cleavage was needed, because activity was not seen with the fusion protein attached (Hara and Yamakawa, 1996). It was shown, that after CNBr cleavage, the activity of the antimicrobial peptide buforin II
was not inhibited by the homoserine residue derived from the Met residue (Lee et al, 1998). Hydroxylamine cleavage was also used (Lee et al, 2000; Hwang et al, 2001) to cleave the Asn-Gly peptide bond engineered between the fusion protein and peptide.

**Our Approach**

As shown above, there are many different variables to review in order to successfully design a system for expressing an antimicrobial peptide. One of the characteristics that make our project unique is the multimerization of the antimicrobial peptide itself. As stated above, the multimerization of an anionic/cationic fusion increased expression levels greatly (Lee et al, 1998). It is hypothesized that, through multimerization of the antimicrobial peptide itself, toxicity of the peptide to the host organism will be decreased by inducing non-native folding without sacrificing expression yields. Utilizing multimerization to reduce toxicity to the host organism will also allow for a greater yield due to the expression of multiple peptides simultaneously. This feature is especially important for the production of indolicidin. As stated above, a proposed mechanism of action of indolicidin involves disrupting DNA synthesis after penetrating the cell membrane. Production of indolicidin in *E. coli* occurs intracellularly and the peptide must therefore remain inactive with respect to DNA synthesis to ensure adequate expression levels. A methionine residue will be utilized to separate the monomers to allow cleavage to produce an active antimicrobial monomer from the multimer by cyanogen bromide cleavage.

Indolidicin and PGQ were chosen for *E. coli* expression because they demonstrated activity against a culture grown from a Navy solid waste puck. These
pucks harbor many microbes and cause a foul odor aboard Navy ships. When a library of antimicrobial peptides was tested against the microbes cultured from the Navy puck (Mello, unpublished), 5 µg of indolicidin and PGQ generated a substantial zone of clearing on an agar plate overlay, while other peptides were less effective or had no activity at all.

Using multimerization techniques, a PGQ-indolicidin hybrid is also being created utilizing a methionine cleavage site to express and purify active PGQ and indolicidin together. This active hybrid can be achieved because indolicidin and PGQ have different amino acid compositions (Figure 6) and different molecular weights. This allows for production of a peptide cocktail. To our knowledge, previously this has not been shown in the literature, nor have multimers of this PGQ-indolicidin hybrid been described.

Multimerization of Peptides

Previous Work

For the past decade, scientists have been working to produce synthetic spider silk to mimic the properties of natural silk. One group of scientists from the Natick Soldier Systems Center has produced synthetic proteins that form recombinant spider silk fibers (Prince et al, 1995). Their methods included multimerizing the DNA sequence for the silk protein repeats in order to obtain the expression of larger proteins. This multimerization process is the approach taken in this thesis for the production of antimicrobial peptides. Multimers of indolicidin, PGQ and indolicidin + PGQ hybrids (hybIP) will be produced using the methods developed with spider silk sequences.
Previous Natick Projects on Indolicidin and PGQ

Richard Beckwitt and Kevin McGrath produced the preliminary work on this project. Beckwitt produced the synthetic genes for Indolicidin and PGQ, and McGrath produced the pUC-link vector. Their work has allowed the multimerization of indolicidin and PGQ for expression studies described in the present project. Beckwitt produced indolicidin monomer, dimer, and trimer genes, and PGQ monomer and trimer genes in the pUC-link cloning vector.

Utilizing the previously constructed monomer antimicrobial genes, indolicidin:PGQ hybrids were created. The restriction sites established during the synthesis of the peptide

A. Nhe I Recognition Site
   GCTAGC
   Spe I Recognition Site
   ACTAGT

B. Correct Orientation
   GCTAGC
   ACTAGC
   ACTAGT
   Incorrect Orientation
   GCTAGC
   ACTAGC
   ACTAGT

Figure 5 Multimerization using Nhe I and Spe I Restriction Sites

A. Shows restriction sites Nhe I and Spe I. These sites are cut after the first base and contain the same middle 4 bases. They are able to be ligated together due to the middle sequence CTAG. When they are ligated together the sequence is unable to be cut by either Nhe I or Spe I. B. When the restriction sites are ligated into the correct orientation, 5’-3’, they create a sequence unable to be cut by Nhe I or Spe I. When they are ligated together in the incorrect orientation, 3’-5’, an Spe I site is created which can be determined by a restriction enzyme digestion.
gene include a 5’ Nhe I site and a 3’ Spe I site (Figures 5 and 6). If the two sites are ligated together in the 5’ - 3’ orientation, they can no longer be cut in the middle by either of these restriction enzymes. This allows for identification of clones with the correct sequence for multiple peptides.

**Figure 6 DNA and Amino Acid Sequence of Indolicidin and PGQ**

DNA and amino acid sequences of indolicidin and PGQ including the addition of the Nhe I and Spe I restriction sites flanking each gene. Methionine residues were also inserted outside each natural gene for the use in cyanogen bromide cleavage following protein expression. Arrows indicate the positions of CNBr cleavage.
**Project Goal**

The goal of this project was to successfully clone and express two active antimicrobial peptides, indolicidin and PGQ, in *E. coli* for mass production at low cost. Currently antimicrobial peptides are expensive to produce and are only available in small quantities by extraction from the host organism or by organic peptide synthesis. Recombinant production should produce peptides in larger quantities at a cheaper cost. Peptides indolicidin and PGQ were chosen due to their previously shown activities against Navy solid waste pucks. These pucks harbor microbe growth and cause a foul odor among Navy ships. A long range goal, outside the scope of this project, is to use these peptides in food preparation surfaces, antimicrobial textiles for biological agent decontamination, and extended wear textiles.
MATERIALS AND METHODS

Vectors Used

pUC-link

pUC-link cloning vector is derived from the pUC-18 plasmid (Appendix 6), by engineering N-terminal and C-terminal Xba I and Bam HI sites, as well as an N-terminal Nhe I site and a C-terminal Spe I site within the pUC-18 multiple cloning site (Prince et al, 1995) (Figure 7). The restriction site insertion was used to regulate directional cloning and multimerization of antimicrobial peptide genes. Blue and white screening of recombinants used in the pUC-18 cloning vector was deactivated as a result of the restriction site insertion. The insertion of the “link” within the lacZ gene disables future lacZ insertion for blue/white screening.

Figure 7 DNA Sequence of Synthetic Adapter Inserted into pUC18 to Create pUC-link

This sequence was inserted into pUC18 to create Nhe I, Spe I and BamHI sites in the cloning vector for multimerization and direct insertion into expression vectors (Prince et al, 1995).

Expression Vectors

Diagrams and features of the expression vectors used in this project are shown in Table 3. Qiagen produces pQE vectors with a 6x His tag at the N-terminus and an optimized promoter-operator. The T5 promoter and the lac operator ensure tight regulation of insert gene expression to prevent uninduced expression. The β-lactamase
gene is incorporated into these plasmids for selection (Qiagen 2000, *The Expressionist*, pg 14).

Novagen created the pET system for *E. coli* expression. All pET vectors are available in three reading frames. The plasmid contains the f1 origin of replication, and the T7 lac promoter using IPTG as the inducer. pET 28a+ contains a C-terminal 6x His tag, T7 tag and no fusion protein. pET 32a+ contains an internal 6x His tag and S-tag along with a 20 kDa N-terminal thioredoxin fusion protein. pET 43.1 a+ contains an internal 6x His tag and S-tag with a N-terminal 66 kDa Nus A fusion protein.

PGEX-4T-2, made by Pharmacia, contains the N-terminal fusion protein Glutathione S-transferase (GST). This system utilizes the *tac* promoter and a thrombin cleavage site. It is provided in all three reading frames and codes for ampicillin resistance and an internal *lac Z* gene for use in any *E. coli* host (see Appendix 1-5 for all vector maps).
Table 3 Expression Vectors Used in this Project

<table>
<thead>
<tr>
<th>Vector</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>6x His Tag</td>
<td>• Contains Thioredoxin fusion protein • BamHI site in MCS • No Nhe I or Spe I sites</td>
<td></td>
</tr>
<tr>
<td>Thrombin Trx S-tag EK MCS pET32 a+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>His Tag</td>
<td>• Contains Nus A fusion protein • BamHI site in MCS • No Nhe I sites</td>
<td>• Contains Spe I site in vector</td>
</tr>
<tr>
<td>Thrombin NusA S-tag EK MCS pET43.1 a+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombin GST MCS pGEX-4T-2</td>
<td>• Contains GST fusion protein • BamHI site in MCS • No Nhe I and Spe I sites</td>
<td>• Lacks T7lac promoter for toxic proteins</td>
</tr>
<tr>
<td>His Tag Thrombin His Tag T7 tag MCS pET28 a+</td>
<td>• Bam HI site in MCS • No Spe I site in vector • C-terminal and N-terminal 6x his tag</td>
<td>• No fusion protein • Contains Nhe I site in vector</td>
</tr>
<tr>
<td>6x His Tag MCS pQE-30</td>
<td>• Bam HI site in MCS • No Nhe I or Spe I in vector</td>
<td>• No fusion protein</td>
</tr>
</tbody>
</table>

Table 3 Expression Vectors Used in this Project

**E. coli Host Strains Used**

**Cloning Host Strains**

The XL1-Blue cloning host strain contains genomic tetracycline resistance, which allows selection of only this *E. coli* strain. This general-purpose propagation host strain enables reproduction of plasmids containing an ampicillin resistance gene (Table 4).
**Host Strains for Expression**

Several expression host strains were chosen (Table 4) based on antibiotic resistance, presence of λDE3 prophage (necessary for expression of T7 RNA polymerase) and demonstrated expression of antimicrobial peptides (Hwang et al, 2001).

**Table 4 E. coli Host Strains**

<table>
<thead>
<tr>
<th>Host Strain</th>
<th>Genotype</th>
<th>Properties</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>XL1-Blue</td>
<td>recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lacI+ proAB lacIq ΔM15 Tn10 (Tet')</td>
<td>General purpose cloning host strain</td>
<td>Stratagene</td>
</tr>
<tr>
<td>JM109DE3</td>
<td>recA1, endA1, gyrA96, thi, hsdR17, (rk-mk+), supE44, Δ(lac-proAB), relA1, [F' traD36, proAB+, lacIqZ, ΔM15] DE3</td>
<td>N/A</td>
<td>Promega</td>
</tr>
<tr>
<td>BL21DE3</td>
<td>Derived from: B-strain, F-, ompT, hsdSb(rb- mb-), gal, dcm (DE3)</td>
<td>General purpose expression host proteolytically deficient</td>
<td>Novagen</td>
</tr>
<tr>
<td>HMS174DE3</td>
<td>Derived from: K-12, F-, recA, hsdR(rk12- mk12+), Rif (DE3)</td>
<td>recA-, K-12 expression host</td>
<td>Novagen</td>
</tr>
<tr>
<td>AD494DE3</td>
<td>Derived from: k-12, Δara-leu7697, ΔlacX74, ΔphoApvuiI, phoR ΔmalF3 F' [lacI+(lacIq)pro] trxB::kan (DE3)</td>
<td>trxB- expression host, allows disulfide bond formation in E. coli cytoplasm</td>
<td>Novagen</td>
</tr>
<tr>
<td>NovablueDE3</td>
<td>Derived from: K-12, recA-, endA-, lacIq, gyrA96, relA1, lac [F' proA+B+, lacIqZΔM15::Tn10(Tcr)trxB::kan (DE3)</td>
<td>recA-, endA-, K-12, lacIq expression host</td>
<td>Novagen</td>
</tr>
</tbody>
</table>
Multimerization of Antimicrobial Peptides

For multimerization, the peptide genes were cut out of the cloning vector by restriction enzyme digestion, ligated to each other and the cloning vector, and transformed into an appropriate *E. coli* host for production and analysis.

The subcloning vector, pUC-link, was digested with Nhe I and Spe I by combining 1 µl of a solution containing 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol, pH 7.9, 10 µg of pUC-link, 1 µl NheI + Spe I (2:1) and 8 µl of water. Digestion reactions were incubated at 37 °C for 1 hour. Digested DNA was analyzed by agarose gel containing 0.045 M Tris-borate, 0.001 M EDTA, pH 8.3, and 1.5% agarose at 85 volts for 1 hour. The inserts were multimerized by combining 20 µg of digested indolicidin or PGQ monomer, 1 µl of T4 DNA ligase (6 units), 1 µl of 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 10 mM dithiothreitol, 1 mM ATP, 25 µg/ml bovine serum albumin, and 8 µl of water and incubating the reaction at 16 °C for 16 hours. The ligation was analyzed by 1.5% agarose gel electrophoresis.

Multimerized indolicidin and PGQ inserts and linear vector bands were extracted from the agarose gel and purified using a Qiagen Gel Extraction Kit. DNA was quantified in a 1.5% agarose gel compared to phi-X174 DNA marker.

Linear vector was dephosphorylated by combining 10 µg of vector, 1 µl of calf intestinal alkaline phosphate, 1 µl of 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol, pH 7.9, 7 µl of water and incubating the reaction mixture at 37°C for 1 hour, followed by heating at 75°C for 10 minutes to denature the enzyme. Ethanol precipitation was then performed to purify the vector for ligation to the insert.
The multimerized inserts were ligated to the dephosphorylated cloning vector in reactions containing 10:1 (insert to vector), 2:1, or no insert control, 1 µl of T4 DNA ligase, 1 µl of a solution containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 10 mM dithiothreitol, 1 mM ATP, 25 µg/ml bovine serum albumin, and 8 µl of water. Reactions were incubated at 16°C for 16 hours. Ligated DNA was transformed into XL1-Blue cells (Stratagene) by adding 50 µl of chemically competent XL1-Blue cells and 2 µl of ligation reactions 10:1 (insert to vector), 2:1 or no insert control mixture. The cell/plasmid mixture was held on ice for 30 minutes, 42°C for 90 sec, then on ice for two minutes. An 800 µl aliquot of SOC (20 g tryptone, 5 g yeast extract, 0.5 g NaCl per liter, autoclave, add 10 µl MgCl₂/MgSO₄ and 20 µl 20% glucose per ml) was added; the cells were then placed at 37°C for five minutes, and then incubated in a 37°C shaker at 250 rpm for one hour. Cells (100 µl) were plated on LB (5 g yeast extract, 10 g NaCl, 10 g peptone, 15 g agar, per liter water) plates supplemented with 50 µg/ml of carbenicillin and 15 µg/ml of tetracycline. Plates were incubated at 37°C overnight.

**Plasmid Analysis**

Several colonies were chosen and inoculated into 4 ml of LB with appropriate antibiotics. Minicultures were grown overnight in a 37°C shaker at 250 rpm. The cells were pelleted at 10,000 x g for 10 minutes at 20°C, and a Qiagen Mini Prep kit was used to purify the plasmid. Plasmid DNA was cut with Bam HI to determine if an insert was present. The restriction digestion was done using 1 µl Bam HI (2 units), 5 µl DNA, 1 µl Bam HI Buffer (150 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol, pH 7.9, 100 µg/ml BSA), and 3 µl water. The reaction was incubated at 37°C for one
hour. The digestion mixture was run on a 4-12% polyacrylamide gel (Novex) in TBE (10.8 g Tris base, 5.5 g Boric acid, 0.58 g EDTA, add water to 1 L and pH to 8.3) buffer at 200V for 30 minutes, placed in 10 µg/ml ethidium bromide for 10 minutes and photographed on a UV light box.

The colonies that contained insert were digested to determine if the correct orientation for transcription of the multimerized insert was produced. This was done by digesting the recombinant vector with both Nhe I and Spe I. If an insert is in the correct orientation, then a band would be observed on the gel at the same size as the insert found previously with Bam HI digestion. If the insert was not in the correct orientation, then the band on an agarose gel would run corresponding to the size of the monomeric gene size.

All clones with the correct orientation were then sent to the Cornell DNA Sequencing Facility where they were sequenced using an Applied Biosystems Automated 3700 DNA Analyzer with Big Dye Terminator chemistry and AmpliTaq-FS DNA Polymerase. Sequences were analyzed with DNA Star software.

Transfer of Insert from pUC-link into Expression Vector

After the insert in pUC-link was determined to be correct by DNA sequencing, it was then subcloned in the expression vector. pUC-link was designed to have a Bam HI site outside the Nhe I and Spe I restriction sites (Figure 7). The pUC-Amp clone and the expression vector were separately digested with Bam HI. The expression vector was subsequently dephosphorylated to prevent self-ligation. The insert and dephosphorylated vector were then ligated using T4 DNA ligase (New England Biolabs) and transformed
into XL1-Blue cells for propagation. After performing a mini-prep isolation of plasmid DNA, restriction digestion with Bam HI, Nhe I, and Spe I, and agarose gel electrophoresis confirmed the presence of an insert.

In vitro Transcription/Translation

In order to test each expression vector/multimerized insert combination for expression, an in vitro transcription/translation method was initially used (Promega). The reactions contained 4 µg of purified expression plasmid containing the AMP insert, 5 µl of minus methionine and minus leucine amino acid mixture to obtain all amino acids, 20 µl of S30 Premix without amino acids, and 15 µl of T7 S30 circular DNA extract in a total volume of 50 µl. The tubes were vortexed and centrifuged for 10 sec at 12,000 x g at 20°C to settle reagents. 1 µl of Transcend biotinylated lysine tRNA (Promega) was added and samples were incubated at 37°C for 1 hour. Samples were then placed on ice for 5 minutes to stop the reaction. An aliquot containing 1/10 of the total volume was removed from the reaction and added to 20 µl acetone and incubated on ice for 15 minutes to precipitate the protein. The samples were spun at 12,000 x g at 20°C in a microcentrifuge for 5 minutes and the supernatant was removed and discarded. To remove the remaining acetone, the samples were lyophilized for 5 minutes. 20 µl 2X SDS sample buffer was added to the lyophilized protein and run on a 10% polyacrylamide gel with 12.1 g/L Tris Base, 17.9 g/L Tricine, 1 g/L SDS running buffer. Proteins were transferred electrophoretically to a PVDF membrane at 2 mA/cm² for 1.5 hours using 25 mM Tris base, 150 mM glycine, 10% methanol, pH 8.3 transfer buffer and detected using streptavidin-alkaline phosphatase conjugate that detects the
biotinylated lysine residues. The membrane was washed for 1 minute in 10 ml of TBS (20 mM Tris-HCL pH 7.5, 150 mM NaCl) at room temperature, then blocked in 25 ml of TBS + 0.5% Tween 20 for 1 hour. The membrane was incubated for 1 hour in 10 ml of TBS + 0.5% Tween 20 and 2 µl streptavidin–alkaline phosphatase (2 mg/ml) to detect the biotinylated lysine incorporated into the protein. The membrane was washed 4X with 25 ml of TBS + 0.5% Tween 20 and color developed using alkaline phosphatase development. 60 µl of 5% nitro blue tetrazolium chloride in 70% dimethylformamide, and 60 µl of 5% 5-bromo-4 chloro-3-indolyl phosphate in 100% dimethylformamide were added to 15 ml of 100 mM Tris-Cl, pH 9.5, mM NaCl, 5 mM MgCl₂. They were incubated with membrane at room temperature for 5 minutes until color developed. To stop the reaction, the membrane was washed in 10 ml of water and dried.

**In vivo Expression of Peptide**

**Small Scale Expression**

Using those constructs that showed expression of the peptide after *in vitro* transcription/translation, a small-scale expression was performed based on The Expressionist method (Qiagen). The expression vector and insert were transformed into M15, SG13009, BL21DE3, BL21DE3pLysS, AD494DE3, HMS174DE3, NovablueDE3, or JM109DE3 cells and plated with appropriate antibiotics. 3 ml of LB with appropriate antibiotics was inoculated with colonies selected from transformation plates. These were grown at 37°C in a shaker at 250 rpm until reading an OD₆₀₀ of 0.6 was reached. A 60 ml culture of LB with antibiotics was inoculated with an aliquot of the overnight culture and grown at 37°C in a shaker at 250 rpm until the OD₆₀₀ read 0.5-0.7. Also, 500 µl of the
starter culture was added to 500 µl of 50% glycerol and placed at -80°C for storage.

When the culture reached mid log phase, 20 ml was removed as uninduced control and the OD$_{600}$ was taken. This uninduced control sample was spun at 10,000 x g for 10 min at 4°C in a centrifuge to pellet the cells. The supernatant was removed by aspiration, and the pellet placed at -20°C for storage. The remaining culture was induced to a 1 mM final concentration (40 µl) of IPTG and placed back in 37°C shaker at 250 rpm for 3 hours. 20 ml samples were taken out at 1.5 hrs and 3 hrs and the OD$_{600}$ was taken. They were pelleted at 10,000 x g for 10 min at 4°C and the supernatant was aspirated off. The pellet was placed in -20°C until the samples were ready for lysis.

The uninduced control and induced samples were removed from the -20°C freezer. An amount of Buffer A (6 M Guanidine, 100 mM NaH$_2$SO$_4$, 10 mM Tris pH 8) determined by 0.7 mls/OD$_{600}$ was added to the pellet to normalize the sample protein concentrations. They were vortexed until the entire cell pellet was in solution. All samples were centrifuged at 15,000 x g for 20 minutes at 4°C to pellet cell debris, and supernatant was removed to a fresh tube.

Each construct and host strain lysate was analysed by western blot to determine which host strain had the largest yield. The samples were run on 4-12 % SDS-PAGE and blotted electrophoretically using semi-dry transfer in 25 mM Bicine, 25 mM Bis-Tris, 1.025 mM EDTA, and 0.05 mM Chlorobutanol onto PVDF membrane at 2 mA/cm$^2$ for 1.5 hours. The membrane was removed from the apparatus and placed into 25 ml of 10 mM Tris-Cl pH 8, 150 mM NaCl (TBS), 0.1% Tween 20, and 1% Gelatin for 15 minutes at room temperature. The buffer was removed and incubated in antibody for the S-tag conjugated with alkaline phosphatase (Novagen). 10 mls of TBS + 0.1% Tween 20 and
1/10,000 antibody was incubated with the membrane at room temperature for 15 minutes. The membrane was washed four times with 25 ml of TBS + 0.1% Tween 20. Alkaline phosphatase detection was performed as stated above.

The samples with the greatest yield were nickel purified to extract only the product of interest from the cell lysis. This was done by adding 100 µl of 50 % Ni/NTA resin equilibrated in Buffer B (8 M Urea, 100 mM NaH₂PO₄, 10 mM Tris pH 8) to 400 µl sample and placing it on a rocker for 1 hr at room temperature. The nickel resin was then added to a 10 cm tall column with a diameter of 1 cm. The flow through was collected in a 1.5 ml microfuge tube. The nickel was then washed with 25 x resin bed volume (1250 µl) Buffer C (8 M Urea, 100 mM NaH₂SO₄, 10 mM Tris pH 6.3). The wash samples were collected in 1.5 ml microfuge tubes, and A₂₈₀ was taken in a spectrophotometer until the fraction reached A₂₈₀ ~0.01. The protein of interest was eluted with 3 column volumes of Buffer E (8 M Urea, 100 mM NaH₂SO₄, 10 mM Tris pH 4.5) in a 1.5 ml microfuge tube. The eluted sample was then analyzed by SDS-PAGE.

**Large Scale Expression and Purification**

Once the construct and host strain with the highest expression yield were chosen, a larger scale expression culture was performed. A 3 ml starter culture of LB with appropriate antibiotics was inoculated with the glycerol stock of the bacteria with construct. This was grown for 8 hrs in 37°C until the OD₆₀₀ reached 0.6. One liter of LB with appropriate antibiotics was then inoculated with the 3 ml starter culture and grown to an OD₆₀₀ of 0.6. A 20 ml sample was removed for the uninduced control and pelleted at 10,000 x g for 10 minutes at 4°C. The culture was induced with IPTG at a final 1 mM
concentration. This was grown for 3 hours at 37°C in a shaking incubator at 250 rpm. The cells were harvested in 250 ml Oakridge tubes and centrifuged for 10 min at 10,000 x g at 4°C. The supernatant was removed and the pellet was placed at -20°C.

The cell pellet was thawed and lysed at a volume 1/50 of culture volume with a solution containing 6 M guanidine chloride (GuCl), 100 mM sodium phosphate (NaH₂PO₄), 10 mM Tris pH 8.0. The pellet was resuspended by vortexing, and pelleted at 15,000 x g for 20 minutes at 4°C. The supernatant was removed and placed into a new tube.

The lysate was purified using a 12.5 cm high x 1.5 cm diameter nickel resin column. The 16 ml of lysate was bound to 4 ml of a 50% slurry of nickel resin equilibrated in 8 M urea, 100 mM NaH₂PO₄, 10 mM Tris base, pH 8.0. This optimum lysate:resin ratio was determined by testing volume ratios of 1:1 lysate to resin, 2:1, 4:1 and 10:1. A ratio of 4:1 was able to bind all available protein and elute the most purified sample. The bound resin/lysate mixture was added to the column after mixing for 1 hour at room temperature. 2 x 16 ml of wash buffer (8 M urea, 100 mM NaH₂PO₄, 10 mM Tris base pH 6.3) was placed over the packed column and collected in 1.5 ml tubes. The absorbance at 280 nm was monitored to determine when all of the unbound protein was washed off. To elute, 6 ml 8 M urea, 100 mM NaH₂PO₄, 10 mM Tris pH 4.5 was placed over the column and collected. Two more elutions were performed using 2 ml elution buffer. The lysate, flow through, final wash sample, and all the elution samples were then analyzed by SDS-PAGE.
**BCA Protein Assay**

Following purification, a BCA protein assay was performed to determine the concentration of the purified protein. 2 ml cuvettes were filled with 100 µl of sample and 2 ml of a 1:50 ratio of reagent A (4% cupric sulfate) and reagent B (sodium carbonate, sodium bicarbonate, bicinechonic acid, sodium tartrate in 0.1 M sodium hydroxide) from Pierce were added. Bovine serum albumin was used as a standard. 50 µl of purified protein was placed in a cuvette with 50 µl water and mixed. Then 2 ml BCA solution was added and incubated at 37°C for 30 minutes. Absorbance at 562 nm was read and the results of the standards were plotted using Excel.

Densitometry was performed following the BCA using SDS-PAGE to determine the percentage of each band within a given sample. Total Lab software was used for these calculations. The amount in each band was calculated based on the total protein amount loaded per lane and the percentage of each band run on SDS-PAGE.

**Cyanogen Bromide Cleavage of Purified Product**

Once nickel purification was completed and the concentration of the products was determined, cyanogen bromide (CNBr) cleavage was performed. The purified sample was first dialyzed to remove urea from the elution buffer. The sample was placed in 12,000-14,000 MW dialysis tubing 1.6 mm in diameter, and dialyzed against 50 volumes of 100 mM NaH2PO4 + 10 mM Tris pH 7.4 for 1 hr, and then the buffer was changed. This was repeated twice and the final buffer exchange equilibrated overnight. The sample in the dialysis tubing was removed and placed in a 1.5 ml tube. The tube was centrifuged at 12,000 x g for 10 minutes at 20°C and the supernatant removed. An aliquot of the
supernatant was run on a 4-12% Bis-Tris NuPAGE Gel for analysis. The insoluble pellet was dissolved in 50 µl of 50 mg/ml CNBr + 70% formic acid. The sample tube was wrapped in aluminum foil and placed on a rocker for 24 hours. To halt cleavage, the sample was placed in a speed-vac to remove CNBr and formic acid for 30 minutes.

The CNBr treated sample pellet was solubilized in 400 µl of 10% acetonitrile and clarified by centrifugation at 12,000 x g for 10 minutes at 20°C and the supernate removed. Both the supernatant and insoluble pellet was run on SDS-PAGE for analysis. Densitometry was performed on the soluble fraction using Total Lab software. The percentage of monomeric peptide in the sample was calculated based on the number and intensity of bands. A BCA was performed to determine the concentration of total protein produced upon CNBr cleavage.

Amino Acid Analysis

Multimerized and CNBr cleaved Ind3 was sent to Commonwealth Biotechnologies for Amino Acid Analysis. 10 µg of peptide was run on an 4-12 % SDS-PAGE gel and blotted onto 0.45 µm PVDF membrane using a semi-dry blotting apparatus and 1X NuPAGE transfer buffer (20 mM Bicine, 25 mM Bis-Tris, 4.1 mM EDTA, 0.2 mM Chlorobutanol pH 7.2) for 1.5 hours at 2 mA/cm². The membrane was stained with 40% Methanol, 0.2% Coomassie Brilliant blue R-250 for 20 minutes and destained in 100% Methanol. The bands were excised and placed in a 1.5 ml tube and 100 µl 100% Methanol was added to completely destain the bands. The membranes were placed in the speed vacuum for 5 minutes to dry. They were sent to Commonwealth Biotechnologies where the membrane pieces were weighed, cut into small pieces and
transferred into pyrolyzed tubes. The samples were hydrolyzed in gas phase 6 N HCl for 90 minutes at 150°C. Following hydrolysis the samples were taken to dryness, and the amino acids present were extracted in 100 µl of 40% Methanol, 0.1 N HCl in HPLC water overnight with occasional vortexing. The extract was combined with a 50 µl rinse of the tube containing the hydrolyzed sample. The extract was taken to dryness, dissolved in 75 µl of sample loading buffer, and 5 µl of the undiluted sample was subjected to analysis.

The pmol amount of each amino acid determined by Commonwealth Biotechnologies was compared to the expected composition of the peptide based on the amino acid sequence. This was performed on an Excel spreadsheet.

**Antimicrobial Activity**

_E. coli_ 0157, _E. coli_ 45827, _S. aureus, S. typhimurium, S. epidermidis_, and bacteria cultured from Navy food pucks, were all tested for antimicrobial growth inhibition by indolicidin and PGQ purchased from Sigma. A plate overlay was performed using MH agar plates (8.75 g acid hydrolysate of casein, 1 g beef extract, 0.75 g starch, 10 g NaCl, 7 g Noble agar, H₂O to 500 ml and autoclave) and M9 agar plates (M9 salts 10X = 15 g Na₂HPO₄, 7.5 g KH₂PO₄, 1.2 g NaCl, 2.5 g NH₄Cl, H₂O to 250 ml. Add 20 ml M9 salts, 3g Bacto agar and 175 ml of H₂O and autoclave). Media was cooled to 55-60°C and 0.2 ml of 1 M MgSO₄, 2 ml of 10 mM CaCl₂, 2 ml of 20% glucose, 0.2 ml of 10 mg/ml thiamine and sterile H₂O were added to 200 ml) and poured into plates. Sigma peptide dissolved to a concentration of 0.5 mg/ml in water was spotted onto a plate in amounts of 5, 10, and 25 µg for each bacterium. 7 ml of top agar (same recipe as
plates with ½ the amount of agar) was autoclaved for 1 minute to melt the agar and cooled to 60°C. 70 µl of an overnight culture of each strain was placed in the top agar, vortexed and poured over the plate. The agar was allowed to dry and plates were placed in 37°C incubator overnight.

The CNBr cleaved sample was tested for activity after determination of monomer concentration by BCA and densitometry. The cleaved sample was placed in the speed vac to concentrate it in order to load 25 µg of peptide monomer on the test plate. 20 µl of peptide solution was spotted onto an MH agar plate along with 20 µl of 10% acetonitrile and 20 µl containing 10 µg of indolicidin from Sigma. 70 µl of an overnight culture of Navy puck bacteria was placed in 7 ml of MH top agar after cooling to 60°C. The top agar was poured over the plate and allowed to cool. The plate was placed at 37°C overnight to form a lawn of bacteria and analyzed for zones of clearing.
RESULTS

The goal of this project was to successfully clone and express two antimicrobial peptides, indolicidin and PGQ in *E. coli* for mass production at low cost. These peptides will then be used in food preparation surfaces, antimicrobial textiles for biological agent decontamination, and extended wear textiles.

Figure 8 Multimerization of Antimicrobial Peptide Genes

The antimicrobial peptide genes are multimerized by utilizing the Nhe I and Spe I restriction sites. To determine if the multimerization resulted in the correct orientation for expression, the inserts were digested with Nhe I and Spe I. If they are in the correct orientation, each monomer will not be released from the insert, whereas if they are in the wrong orientation, monomeric units will be seen by agarose gel electrophoresis.
Multimerization of Antimicrobial Peptides via DNA Cloning

Several multimers of indolicidin and PGQ encoding DNAs were created, along with several hybrid DNAs encoding indolicidin:PGQ multimeric genes. Previous work created indolicidin monomer, dimer, and trimer genes, and PGQ monomer, dimer and trimer genes. Utilizing the methods described (Figure 8) and previously created constructs, Ind6, PGQ6, hybIP (not indicated in gel), hybIPP (not indicated in gel) and hyb(IP)_2 were created and placed into pUC-link for propagation. Figure 9 shows the sizes of several DNA multimers cut with Bam HI to remove the entire cloned insert.

Figure 9 Determination of Correct Insertion of Multimerized DNA Insert

Agarose gel analysis of multimerized antimicrobial peptide genes cloned into pUC-link. All samples are digested with BamHI and run on a 1.5% agarose gel to determine if they are the correct size. All samples shown were of correct size. Lane 1 PGQ1, lane 2 PGQ3, lane 3 PGQ6, lane 4 Ind1, lane 5 Ind3, lane 6 Ind6, lane 7+8 Hyb(IP)_2, M is Phi X 174 marker (NEB).
Cornell DNA Sequencing Results

Following insert size verification of each plasmid construct (Figure 9), sequencing was performed to determine if the gene contained any mutations. The inserts were also sequenced again after placement of the peptide-coding insert into the expression vector (Figure 10) to verify that the DNA was in the correct reading frame. The results were analyzed with DNA Star software. All sequences conformed to the expected outcome (See Appendix 7-13).

Expression in pQE-30

Small-scale *in vivo* expression (inducing a small culture of cells using IPTG) (Figure 10) was used to determine if the plasmids encoding multimerized antimicrobial peptides were expressed in both M15 and SG13009 cells. Expression was tested with pQE-30:PGQ3 (trimer), which should produce a 12 kDa protein. The plasmid pQE-40 containing a dihydrofolate reductase gene (DHFR 26 kDa) was used as a positive expression control. Figure 11 represents an SDS-PAGE depicting the expression levels of DHFR and PQE-30:PGQ3. Under induction conditions, even in the complex mixture, DHFR can be seen above all other background proteins (lanes 3, 8, 9). However, no evidence of 12 kDa PGQ3 expression was obtained in this expression system (lanes 6, 7, 11, 12). Expression was tested with pQE-This small-scale expression of pQE-30:PGQ3 was performed multiple times with the same negative result (Figures 11 + 12). Both cell lysate (Figure 11) and nickel purified samples (Figure 12) were run on SDS-page gels to determine if PGQ3 was expressed. Only the induced positive control showed a band around 26 kDa.
After creation of AMP multimer gene, it was inserted into pUC-link and propagated. Inserts found to be in the correct orientation were extracted by BamHI digestion and inserted into an expression vector. It was then transformed into an expression host strain and expression was induced with IPTG to produce the recombinant multimerized peptide. The multimeric peptide was cleaved with cyanogen bromide to created monomeric peptide.

**Figure 10 Cloning and Expression of Multimerized Antimicrobial Peptide Genes in E. coli**
Figure 11 SDS-PAGE Analysis of Cell Lysates

Cell lysates of small-scale expression of pQE-30 with PGQ 3 insert in host strains SG13009 and M15 induced and uninduced samples. Only expression of the positive control pQE-40 with DHFR protein was observed. No expression of PGQ 3 was seen. M = mark-12 molecular weight marker; lane 2 uninduced SG13009 pQE-40; lane 3 induced SG13009 pQE-40; lane 4 uninduced SG 13009 pQE-40; lane 5 uninduced SG13009 pQE-30:PGQ3; lane 6 induced SG13009 pQE-30:PGQ3; lane 7 induced SG13009 pQE-30:PGQ3; lane 8 induced M15 pQE-40; lane 9 induced M15 pQE-40; lane 10 uninduced M15 pQE-30:PGQ3; lane 11 induced M15 pQE-30:PGQ3; lane 12 induced M15 pQE-30:PGQ3.
Nickel purification of pQE-30 PGQ3 small-scale expression in SG13009 and M15 host strains. After purification only pQE-40 DHFR positive control showed expression as predicted with a 26 kDa protein and purification using 6x His tag. No PGQ3 was expressed. M = mark 12 molecular weight marker; lane 2 SG13009 uninduced pQE-40; lane 3 SG13009 induced pQE-40; lane 4 SG13009 induced pQE-40 no expression of DHFR; lane 5 SG13009 uninduced pQE-30:PGQ3; lane 6 SG13009 induced pQE-30:PGQ3; lane 7 SG13009 induced pQE-30:PGQ3; lane 8 M15 induced pQE-40; lane 9 M15 induced pQE-40; lane 10 M15 induced pQE-30:PGQ3; lane 11 M15 induced pQE-30:PGQ3; lane 12 M15 induced pQE-30:PGQ3.

Expression in Other Host Strains

Due to the lack of expression of pQE-30:PGQ3, another non-fusion expression vector, pET28a+, was used to test for expression. Both PGQ3 and PGQ6 were placed into the expression vector and small-scale expression performed. Unfortunately with pQE-30, no expression was achieved under conditions that strongly expressed DHFR (data not shown). Due to this result, fusion proteins were explored as an alternate means...
of expression based on data from peer-reviewed journals. Several fusion protein expression vectors were available that should produce peptide in the correct reading frame. These vectors included pET32a+ with a thioredoxin fusion, pET43.1a+ with a NusA fusion, and pGEX-4T-2 containing a GST fusion. Due to the large number of multimerized inserts created and the variety of vectors available, it was decided to perform in vitro transcription/translation to quickly determine which expression vectors produce the recombinant peptide.

In vitro Transcription/Translation

The constructs were tested by in vitro transcription/translation with biotinylated lysine tRNA using streptavidin-alkaline phosphatase to determine if expression was possible.

<table>
<thead>
<tr>
<th>Expression Vector</th>
<th>AMP Insert</th>
<th>In Vitro Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>pQE-30</td>
<td>PGQ 3mer</td>
<td>No</td>
</tr>
<tr>
<td>pET28a+</td>
<td>PGQ 3mer</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Indolicidin 1mer</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>PGQ 1mer</td>
<td>No</td>
</tr>
<tr>
<td>pET32a+ Thioredoxin fusion (Trx)</td>
<td>PGQ 6mer</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Indolicidin 3mer</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>(Indolicidin + PGQ)₂</td>
<td>Yes</td>
</tr>
<tr>
<td>pET43.1a+ NusA fusion</td>
<td>PGQ 6mer</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Indolicidin 3mer</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>(Indolicidin + PGQ)₂</td>
<td>No</td>
</tr>
<tr>
<td>pGEX-4T-2 GST fusion</td>
<td>PGQ 6mer</td>
<td>No</td>
</tr>
</tbody>
</table>

Table 5 Vectors and Inserts used for In Vitro Transcription/Translation

In vitro transcription/translation resulted in all inserts within pET32a+ and PGQ 6 in pET43.1a+ expressing the correct size peptide.
The results of this in vitro expression experiment (Table 5) confirmed that both pQE-30 and pET28a+ did not express PGQ3 (data not shown). The inserts were placed into pET28a+ and tested for in vitro expression (Table 5). In contrast to the negative data obtained with non-fusion proteins, several expression vectors containing the fusion protein displayed positive expression in vitro.

The in vitro reactions were analyzed by detection of biotinylated protein products to determine if the predicted protein size is present after translation. A protein product of the appropriate size was detected with the fusions (Figure 13 lanes 3, 4, 5, 6) NusA:PGQ6, Trx:PGQ6, Trx:Ind3, and Trx:hyb(IP)2. However, no product was seen with GST:PGQ6 or pET28:PGQ6 (lanes 7 and 8).

![Figure 13: In Vitro Transcription/Translation Results](image)

The end product from in vitro transcription/translation was run on SDS-PAGE and blotted electrophoretically onto PVDF membrane. Streptavidin conjugated alkaline phosphatase was incubated with the membrane and exposed to alkaline phosphatase color development showing all biotinylated proteins expressed in vitro. M = biotinylated protein marker; Lane 1 – control no vector; Lane 2 + control pinpoint vector (Promega) with 39 kDa band; Lane 3 NusA:PGQ6 showing 85 kDa band; Lane 4 Trx:PGQ6 showing 40 kDa band; Lane 5 Trx:Ind3 showing 29 kDa band; Lane 6 Trx:hyb(IP)2 showing 32 kDa band; Lane 7 GST:PGQ6 showing no bands corresponding to predicted 45 kDa; Lane 8 pET28:PGQ6 showing no 26 kDa band.
In vivo Expression in Different Host Strains

The vectors demonstrating positive in vitro expression were transformed into several E. coli host strains to evaluate in vivo expression levels. The host strains were chosen based on vector compatibility, proteolytic deficiency, and citations in peer-reviewed journals. Five host strains were chosen and compared by small-scale expression and western blots. For comparison, (Figures 14-17) the amount of lysate loaded on SDS-PAGE were normalized based on optical density at each sample collection. All constructs contained an S-tag for antibody and alkaline phosphatase detection. The results in Figures 14-17 show that BL21DE3 (lanes 2 & 3) and AD494DE3 (lane 4 & 5) show the greatest expression yield. All host strains expressed the antimicrobial gene, but some weren’t as efficient as others. Ultimately BL21DE3 and AD494DE3 were chosen to carry on further experiments with purification of the protein based on the intensity of the western blot bands including NusA:PGQ6, Trx:Ind3, and Trx:(IP)2.
Figure 14 Expression of Trx:PGQ6 in Various Host Strains

Small-scale expression of Trx:PGQ6. The sample was run on 4-12% SDS PAGE, electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and alkaline phosphatase detection. BL21DE3 and AD494DE3 cells showed the greatest expression level after 1.5 hours of induction. Lane 1 Trail Mix Western Markers; Lanes 2 and 3 BL21DE3 after 1.5 and 3 hours of induction shows expression; Lanes 4 and 5 AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 7 HMS174DE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 8 and 9 NovablueDE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 10 and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows little expression; Lane 12 pET32a+ positive control after 3 hours shows predicted 20 kDa band.
Figure 15 Expression of NusA:PGQ6 in Various Host Strains

Small-scale expression of NusA:PGQ6. The sample was run on 4-12% SDS PAGE, electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and alkaline phosphatase detection. Lane 1 Trail Mix Western Markers; Lanes 2 and 3 BL21DE3 after 1.5 and 3 hours of induction shows little expression; Lanes 4 and 5 AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 7 HMS174DE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 8 and 9 NovablueDE3 cells after 1.5 and 3 hours of induction shows little expression; Lanes 10 and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows little expression; Lane 12 pET43.1a+ positive control after 3 hours shows predicted 65 kDa band.
Small-scale expression of Trx:Ind3. The sample was run on 4-12% SDS PAGE, electroblotted onto PVDF membrane, and detected using an S-tag AP antibody and alkaline phosphatase detection. BL21DE3 and AD494DE3 cells showed the greatest expression level after 1.5 or 3 hours of induction. Lane 1 Trail Mix Western Markers; Lanes 2 and 3 BL21DE3 after 1.5 and 3 hours of induction shows expression; Lanes 4 and 5 AD494DE3 cells after 1.5 and 3 hours of induction shows expression; Lanes 6 and 7 HMS174DE3 cells after 1.5 and 3 hours of induction show no expression of predicted 29 kDa band; Lanes 8 and 9 NovabluDE3 cells after 1.5 and 3 hours of induction shows no expression; Lanes 10 and 11 JM109DE3 cells after 1.5 and 3 hours of induction shows no expression; Lane 12 pET32a+ positive control after 3 hours shows predicted 20 kDa band.
Expression and Purification of Selected Constructs and Host Strains

Based on the above observations, the conditions chosen for scale-up of expression were BL21DE3 and AD494DE3 cells induced for 3 hours. 1 L cultures expressing NusA:PGQ6, Trx:Ind3, and Trx:hyb(IP)_2 were grown for 3 hrs and purified using a Ni/NTA column. Figure 18 shows very strong expression of Trx:Ind3 (lanes 4 & 5) with only minor contaminants after column purification (lane 5).
Figure 18 SDS-PAGE of NusA:PGQ6, Trx:Ind3, Trx:hyb(IP)_2 Cell Lysates and Nickel Purified.

NuPAGE 4-12% Bis-Tris gel of large-scale expression lysates. Gel was stained with coomassie blue. Trx:Ind3 showed the greatest expression yield. Lane 1 M12 marker; Lane 2 NusA:PGQ6 cell lysis sample; Lane 3 NusA:PGQ6 purified sample; Lane 4 Trx:Ind3 cell lysis sample; Lane 5 Trx:Ind3 purified sample; Lane 6 Trx:hyb(IP)_2 cell lysis sample; Lane 7 Trx:hyb(IP)_2 purified sample

Cyanogen Bromide Digestion of Purified Product

The presence of Met residues allows separation of the Ind multimers by cyanogen bromide cleavage (Figure 19). A CNBr digest was performed on nickel purified Trx:Ind3 to cleave the multimerized peptide/fusion protein and obtain indolicidin monomer (Figure 20).
Figure 19 Cyanogen Bromide Cleavage Site in Multimerized Peptide

Met labeled arrows indicate where the multimeric peptide is cleaved by cyanogen bromide treatment.

Figure 20 CNBr Cleavage of Trx:Ind3

CNBr cleaved Trx:Ind3 sample run on NuPAGE 4-12% Bis-Tris gel and stained with coomassie. Ind1 shows correct size decrease after CNBr cleavage. Lane 1 represents M12 molecular weight Marker; Lane 2 represents CNBr cleaved Trx:Ind3 (predicted size of Ind monomer is 2.0 kDa); Lane 3 represents uncleaved TrxInd3 (predicted size is 29 kDa).
Prior to CNBr cleavage, the 8 M Urea was dialyzed from purified samples to precipitate the protein product. Products of CNBr cleavage were analyzed by SDS-PAGE (Figure 20). Although larger products were also obtained due to cleavage of the fusion protein, a product of the correct size for Ind monomer was observed.

Several different buffers including 20 mM Tris pH 7.5, 6 M guanidine, 30% acetonitrile, and 10% acetic acid were tested to solubilize the pelleted product after cleavage based on literature descriptions (Ponti et al, 1999; Haught et al, 1998; Lee et al, 1998). Each buffer solution was tested for antimicrobial activity to determine if they could be used for activity assays by bacterial overlays. Ten percent acetic acid was the only solution to show any antimicrobial activity and thus was not used for resolubilization. The concentrations of acetonitrile and Gdn-HCl were decreased to 10% and 4 M respectively due to their incompatibility with the BCA protein assay performed prior to the antimicrobial activity assay. Ten percent acetonitrile was chosen for solubilization because 20 mM Tris did not solubilize the peptide completely, and 4 M guanidine became insoluble upon concentrating the sample, due to the large volume needed for solubilization.

A BCA protein assay and gel densitometry of the CNBr cleaved solubilized product were performed to predict the amount of monomer produced per ml of dialyzed nickel purified product. The concentration of the entire cleaved sample ranged from 0.3 to 0.7 µg/µl in a 600 µl sample of solubilized product.
Amino Acid Analysis

Amino acid analysis was performed by Commonwealth Biotechnologies on the Trx:Ind3 nickel purified protein product. Tryptophan is unable to be detected using the acid hydrolysis method of amino acid analysis, thus resulting in a large discrepancy in the percent difference reported in Table 6. All other amino acid percentages were within range of the predicted composition.

<table>
<thead>
<tr>
<th>Amino Acid</th>
<th>% Comp Actual</th>
<th>% Comp observed</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASX</td>
<td>9.1%</td>
<td>8.5%</td>
<td>0.6%</td>
</tr>
<tr>
<td>GLX</td>
<td>4.9%</td>
<td>6.1%</td>
<td>-1.2%</td>
</tr>
<tr>
<td>CYS</td>
<td>0.8%</td>
<td>2.8%</td>
<td>-2.0%</td>
</tr>
<tr>
<td>ALA</td>
<td>7.2%</td>
<td>7.3%</td>
<td>-0.1%</td>
</tr>
<tr>
<td>PHE</td>
<td>1.9%</td>
<td>2.5%</td>
<td>-0.6%</td>
</tr>
<tr>
<td>GLY</td>
<td>6.8%</td>
<td>8.0%</td>
<td>-1.2%</td>
</tr>
<tr>
<td>HIS</td>
<td>3.8%</td>
<td>2.1%</td>
<td>1.7%</td>
</tr>
<tr>
<td>ILE</td>
<td>6.1%</td>
<td>5.2%</td>
<td>0.9%</td>
</tr>
<tr>
<td>LYS</td>
<td>6.8%</td>
<td>5.0%</td>
<td>1.8%</td>
</tr>
<tr>
<td>LEU</td>
<td>9.5%</td>
<td>9.4%</td>
<td>0.1%</td>
</tr>
<tr>
<td>MET</td>
<td>4.9%</td>
<td>2.4%</td>
<td>2.5%</td>
</tr>
<tr>
<td>PRO</td>
<td>8.0%</td>
<td>8.7%</td>
<td>-0.7%</td>
</tr>
<tr>
<td>ARG</td>
<td>5.3%</td>
<td>8.4%</td>
<td>-3.1%</td>
</tr>
<tr>
<td>SER</td>
<td>7.6%</td>
<td>9.4%</td>
<td>-1.8%</td>
</tr>
<tr>
<td>THR</td>
<td>7.2%</td>
<td>7.5%</td>
<td>-0.3%</td>
</tr>
<tr>
<td>TYR</td>
<td>0.8%</td>
<td>2.5%</td>
<td>-1.7%</td>
</tr>
<tr>
<td>VAL</td>
<td>2.3%</td>
<td>4.3%</td>
<td>-2.0%</td>
</tr>
<tr>
<td>Trp</td>
<td>6.8%</td>
<td>0.0%</td>
<td>*6.8%</td>
</tr>
</tbody>
</table>

Table 6 Amino Acid Analysis Trx:Ind3 Purified Sample

*Cys and Trp cannot be detected by the hydrolysis performed. Observed Cys is actually Cystine detected.

Quantitation

Quantitation of yield of nickel purified and cyanogen bromide treated Trx:Ind3 was determined based on BCA assays and densitometry. Following nickel purification, a BCA was performed to determine the total protein concentration. Densitometry was then performed using Total Lab software after running the nickel purified sample by SDS-
PAGE and coomassie staining (Table 7). The calculated molecular weight of Trx:Ind3 is 28.951 kDa. The percentage of Ind1 within this protein by mass is 21%. After cyanogen bromide cleavage, the sample was run by SDS-PAGE and coomassie staining to determine the actual yield of Ind1. Upon densitometry, the Ind1 band was determined to be from 24-46% of the CNBr cleaved sample compared to the predicted 21% of sample. This predicts that there is more than 1 protein corresponding to the 2 kDa band comigrating with the indolicidin monomer (see Figure 20).

<table>
<thead>
<tr>
<th>µg in 1 L cultured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total nickel purified protein (BCA assay)</td>
</tr>
<tr>
<td>% Trx:Ind3 after densitometry</td>
</tr>
<tr>
<td>Final amount of Trx:Ind3</td>
</tr>
<tr>
<td>% Ind1 of Trx:Ind3 after densitometry</td>
</tr>
<tr>
<td>Final yield of Ind1</td>
</tr>
</tbody>
</table>

**Table 7 Quantitation of Indolicidin Monomer**

Quantitation is calculated based on a BCA of total protein after nickel purified sample of a 1 L culture followed by densitometry of sample on polyacrylamide gel. The percent of Ind1 within nickel purified product is calculated based on the 2 kDa size of Ind1 as compared to the 29 kDa size of Trx:Ind3.

**Antimicrobial Activity Assay**

Several bacterial strains and Navy solid waste puck microbes were tested to determine whether commercial samples of indolicidin and PGQ were active. Only the Navy puck bacteria (unpublished) on MH agar exhibited a zone of clearing with less than 25 µg of peptide; the puck bacteria required only 5 µg of commercially available indolicidin or PGQ for a 1 cm zone of clearing (data not shown). *E. coli* 0157, *E. coli* 45827, *S. aureus*, *S. typhimurium*, and *S. epidermidis* all required more than 25 µg of peptide, or did not show any zones of clearing with 50 µg of peptide (data not shown).
CNBr cleaved Trx:Ind3 solubilized in 10% Acetonitrile was tested for activity with the Navy puck bacteria on MH agar plates. 25 µg of monomeric peptide revealed a 1 cm hazy zone of clearing (Figure 21, lower right), where the 10% Acetonitrile control did not (lower left). These data indicates that cyanogen bromide cleaved Ind3 produces active peptide. CNBr cleaved Trx control was also tested for antimicrobial activity along with nickel purified Trx:Ind3 to determine whether only CNBr cleaved Ind1 shows antimicrobial activity against the microbes cultured from the Navy puck. No zones of clearing occurred with either the CNBr cleaved Trx control (Figure 22) or nickel purified Trx:Ind3 (data not shown).

**Figure 21 Plate Overlay of Cyanogen Bromide Digested Trx:Ind3**

This figure shows the zone of clearing of indolicidin from sigma (upper left) and recombinant indolicidin (lower right). The 10% Acetonitrile control (lower left) showed no zones of clearing. This overlay was performed using MH agar and Navy puck bacteria.
Figure 22 Plate Overlay of Cyanogen Bromide Digested Trx fusion protein

This figure demonstrates no antimicrobial activity of the Trx fusion protein alone following cyanogen bromide cleavage. This control is needed as cleavage of the fusion protein may have resulted in peptide fragments with antimicrobial activity.
DISCUSSION

Natural Indolicidin vs. Recombinant Indolicidin

Natural indolicidin is a 13 amino acid peptide, which is aminated at the carboxyl terminus (Falla et al, 1996). The recombinant indolicidin produced by *E. coli* does not contain an aminated carboxyl terminus and contains a methionine residue at the N-terminus. This is a product of the cyanogen bromide cleavage utilized in the multimerization technique to produce indolicidin. This methionine residue is also contained in the constructs of recombinant peptides described in published studies (Lee et al, 1998. Zhang et al, 1998. Lee et al, 2000. Ponti et al, 1999), in which it was determined not to affect the antimicrobial activity of the peptides produced. Antimicrobial activity of recombinant indolicidin versus natural indolicidin has not been investigated prior to this study. Recombinant Ind1 shows similar size zones of clearing following cyanogen bromide cleavage, although purification must be done in order to attribute these results to recombinant Ind1.

Vectors and Host Strains

Initially only pQE-30 and pET28a+ were chosen as expression vectors for the multimerized peptides due to their ability to express toxic proteins fused to a 6x His tag. When neither of these constructs produced any recombinant protein, other expression systems were found by searching the literature for features of successful antimicrobial peptide expression systems. Vectors expressing a fusion protein were chosen based on multiple articles stating that low peptide, or no peptide, was produced without a fusion protein (Ponti et al, 1999; Zhang et al, 1998; Harrison et al, 1999). While previous studies
created their own fusion proteins, the fusions we used were chosen from commercial vectors containing BamHI restriction sites and possessing the ability to express the peptides in the correct reading frame. This resulted in choosing pET43.1a+ (Nus A fusion), pET32a+ (thioredoxin fusion), and pGEX-4T-2 (GST fusion).

After selection of expression vectors, several different host strains were chosen from those described in the literature that produced the highest expression levels. This literature search resulted in the choice of BI21DE3 (Lee et al, 1998 and Ponti et al, 1999), HS174DE3 (Lee et al, 2000), and JM109 (Taguchi et al, 1994). These host strains differed not only in antimicrobial peptide expression, but also in properties such as proteolytic deficiencies, solubilization of recombinant proteins, or derivation from different cell strains.

**In vitro Transcription/Translation**

*In vitro* transcription/translation was deemed necessary following the inability to successfully express the peptide genes in pQE-30 or pET28a+. Although the literature led us to expect that low yields of peptide would be expressed even without a fusion protein (Zhang et al, 1998) no expression was seen. These experiments determined that the only constructs expressed *in vitro* were those in fusion protein vectors.

The lack of *in vitro* expression of the non-fusion protein vectors may be due to truncated expression of the peptides, or incorrect transcription or translation from the expression vectors. This *in vitro* transcription/translation system is designed to express plasmids with both *E. coli* promoters and T7 promoters. This was chosen because all pET vectors contain T7 promoters.
Expression and Purification of Selected Constructs

Once the constructs were chosen for *in vivo* expression and purification, the optical density (OD) of each induced culture was monitored to determine whether cell growth halted or decreased following induction as seen in expression of pQE-30 and pET28a+ constructs. Trx:Ind3 showed a large increase in OD during induction as expected of a productive culture in log phase growth. Both Trx:hyb(IP)2 and NusA:PGQ6 showed a leveling off of cell growth following induction (data not shown). This may have resulted in the lower expression levels of those constructs.

Cyanogen bromide cleavage originally posed a problem because the purified expression protein was in a solution containing 8 M urea; this affected the antimicrobial activity of the sample following cyanogen bromide cleavage due to formic acid remaining in the sample. This was resolved by dialyzing the urea away into a non-denaturing buffer, thus making the protein insoluble. The cyanogen bromide digestion itself allowed the purified protein to become soluble in the formic acid, and all formic acid was removed during lyophilization.

Another hurdle before activity could be tested included the re-solubilization of the cyanogen bromide cleaved peptide product. Several solvents were tested for antimicrobial activity, resulting in the use of 10% acetonitrile.

Quantitation

Comparing expression yields with those described in the literature was not straightforward. Each article reviewed utilizes a slightly different method of production,
purification and quantitation of the peptide produced, making it difficult to directly compare the yield. Quantitation of yield for the recombinant Ind1 was only theoretically calculated and not determined directly. This calculation was based on BCA and densitometry of the nickel purified Trx:Ind3 sample of a 1L shake flask culture. Lee et al. (1998), calculated a final concentration of 107 mg/L of purified antimicrobial peptide produced in a 30 L high cell density fermentation, based on BCA. Haught et al. (1997) calculated 0.37 mg/L of purified peptide product from 1 L shake flask fermentation based on BCA and densitometry after solubilization of inclusion bodies, similar to the method used here. This suggests that the 1 L shake flask culture yields in the literature ranging from 0.37-1 mg/L purified active peptide, may be directly compared to the yield of 0.5 mg/L we obtained with Trx:Ind3. It is hypothesized that after high cell density expression large yields such as those obtained by Lee et al. (1998) may be achieved with Trx:Ind3.

Summary

Multimerization proved to be successful for expression of recombinant indolicidin. While this type of multimerization is novel for antimicrobial peptide production, many factors of protein expression remained similar to other studies. As observed by others, the use of a fusion protein was necessary to express the peptide multimer. Fusion proteins are used to hide the peptide from proteolytic cleavage as well as hide the toxicity of the antimicrobial peptide. It was thought that multimerization of the peptide itself would be sufficient to mask the toxicity to the producing E. coli cells, but this was found to be untrue. Lee et al. (1998), Ponti et al. (1999), Haught et al.
(1998), and Piers et al. (1993), inserted a methionine to cleave their peptide away from
the fusion protein during purification. Methionine residues flanking the peptide gene
were used to cleave the multimers during purification.

Several differences between published literature and the multimerized peptide
expression described here include the determination of antimicrobial activity and
purification method. While most peptides were purified as inclusion bodies, indolicidin
was solubilized and passed over a Ni/NTA resin for purification via the 6x His tag. For
determination of antimicrobial activity, bacterial agar overlays were used by spotting
CNBr cleaved peptide on agar plates, overlaying an agar suspension of growing bacteria,
and looking for zones of clearing. Only Piers et al. (1993) used a similar overlay method.
All other published studies used liquid micro-titer plate cultures. The main difference
between other studies and ours was the purity of the peptide used in activity testing. In
our study, indolicidin monomer was not purified, while purified peptides were used in all
other studies. Purification of the CNBr cleaved sample needs to be performed to
compare the actual concentration of recombinant indolicidin to that of natural indolicidin.


Appendix 1 Vector Map of pET28a+
Appendix 2 Vector Map of pET32a+

![Diagram of pET32a+ vector map](image)

**pET-32a(+)**

(6000bp)

**17 terminators**

- **T7 promoter**
- **lac operator**
- **Xba I**
- **rbs**

**T7 terminator**

**T7 terminator primer #1 (5'-GCTCGAG-3')**
Appendix 3 Vector Map of pET43.1a+

[Diagram of pET43.1a+ vector map showing various restriction sites, promoters, and cloning regions.]

pET-43.1a(+) cloning/expression regions

---

71
Appendix 4 Vector Map of pQE-30
Appendix 5 Vector Map of pGEX-4T-2
Appendix 6 Vector Map of pUC18

pUC18
2686 bp
Appendix 7 Sequencing Results of Ind3 in pUC-link

Ind 3 Predicted  GCTAGCATGATCCTGCCGTGGAAATGGCCGTGGTGGC  
                  ******************************************  
Ind 3 Actual    GCTAGCATGATCCTGCCGTGGAAATGGCCGTGGTGGC  
                  CGTGGCGTCGTATGACTAGCATGATCCTGCCGTGGAAA  
                  ******************************************  
                  CGTGGCGTCGTATGACTAGCATGATCCTGCCGTGGAAA  
                  TGGCCGTTGTTGCCGTGGCCGTGTATGACTAGCATGAT  
                  ******************************************  
                  TGGCCGTTGTTGCCGTGGCCGTGTATGACTAGCATGAT  
                  CCGTGCTTAATGGCCGTGGCCTGCCGTGGCTCGTA  
                  ******************************************  
                  CCGTGCTTAATGGCCGTGGCCTGCCGTGGCTCGTA  
                  TGACTAGT  ******************  
                  TGACTAGT
Appendix 8 Sequencing Results of Ind6 in pUC-link

<table>
<thead>
<tr>
<th>Ind 6 Predicted</th>
<th>GCTAGCATGATCCTGCCGTTGAATGGCCGTGGTGG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ind 6 Actual</td>
<td>GCTAGCATGATCCTGCCGTTGAATGGCCGTGGTGG</td>
</tr>
<tr>
<td></td>
<td>CCGTGGCGTCGTATGACTAGCATGATCCTGCCGTTG</td>
</tr>
<tr>
<td></td>
<td>CCGTGGCGTCGTATGACTAGCATGATCCTGCCGTTG</td>
</tr>
<tr>
<td></td>
<td>AATGGCCGTGCGGTGCGGTGCGTCGTATGACTAGCAT</td>
</tr>
<tr>
<td></td>
<td>AATGGCCGTGCGGTGCGGTGCGTCGTATGACTAGCAT</td>
</tr>
<tr>
<td></td>
<td>GATCCTGCCGTTGGAAATGGCCGTGTTGCCGTCGTG</td>
</tr>
<tr>
<td></td>
<td>GATCCTGCCGTTGGAAATGGCCGTGTTGCCGTCGTG</td>
</tr>
<tr>
<td></td>
<td>CGTATGACTAGCATGATCCTGCCGTTGGAAATGGCCGT</td>
</tr>
<tr>
<td></td>
<td>CGTATGACTAGCATGATCCTGCCGTTGGAAATGGCCGT</td>
</tr>
<tr>
<td></td>
<td>GGTGGCCGTGGCCGTGCGTATGACTAGCATGATCCTGCC</td>
</tr>
<tr>
<td></td>
<td>GGTGGCCGTGGCCGTGCGTATGACTAGCATGATCCTGCC</td>
</tr>
<tr>
<td></td>
<td>GTGGAAATGGCCGTGTTGCGGCGTTCGTATGACT</td>
</tr>
<tr>
<td></td>
<td>GTGGAAATGGCCGTGTTGCGGCGTTCGTATGACT</td>
</tr>
<tr>
<td></td>
<td>AGCATGATCCTGCCGTTGGAAATGGCCGTGTTGCGGCGT</td>
</tr>
<tr>
<td></td>
<td>AGCATGATCCTGCCGTTGGAAATGGCCGTGTTGCGGCGT</td>
</tr>
<tr>
<td></td>
<td>GGCCTCGTATGACTAGT</td>
</tr>
<tr>
<td></td>
<td>GGCCTCGTATGACTAGT</td>
</tr>
</tbody>
</table>
### Appendix 9 Sequencing Results of IP in pUC-link

<table>
<thead>
<tr>
<th>IP Predicted</th>
<th>GGATCCATGGCTAGCATGGGTGTTCTGTCTAACCCTTATC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td>IP Actual</td>
<td>GGATCCATGGCTAGCATGGGTGTTCTGTCTAACCCTTATC</td>
</tr>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td></td>
<td>GGTTACCTGAACAGATGACTAGCATGATCCTGCTCACGCT</td>
</tr>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td></td>
<td>GGTTACCTGAACAGATGACTAGCATGATCCTGCTCACGCT</td>
</tr>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td></td>
<td>GTTCTGAAACAGATGACTAGCATGATCCTGCTACGCT</td>
</tr>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td></td>
<td>GTTCTGAAACAGATGACTAGCATGATCCTGCTACGCT</td>
</tr>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td></td>
<td>TGGCCGTGTCGCGGCACGTGACTAGCTAGTGGATCC</td>
</tr>
<tr>
<td></td>
<td>******************************************</td>
</tr>
<tr>
<td></td>
<td>TGGCCGTGTCGCGGCACGTGACTAGCTAGTGGATCC</td>
</tr>
</tbody>
</table>
Appendix 10 Sequencing Results of (IP)$_2$ in pUC-link

<table>
<thead>
<tr>
<th>(IP)$_2$ Predicted</th>
<th>GCTAGCATGGGTGTCTCTTCTAACCCTATCGGTGTTA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(IP)$_2$ Actual</td>
<td>GCTAGCATGGGTGTCTCTTCTAACCCTATCGGTGTTA</td>
</tr>
<tr>
<td></td>
<td>CCTGAAAAACTGGGTACCCGTGCTCTGACACGTGAC</td>
</tr>
<tr>
<td></td>
<td>CCTGAAAAACTGGGTACCCGTGCTCTGACACGTGAC</td>
</tr>
<tr>
<td></td>
<td>TTCTGAAACGACTAGCATGATCCTGCACGTGAC</td>
</tr>
<tr>
<td></td>
<td>TTCTGAAACGACTAGCATGATCCTGCACGTGAC</td>
</tr>
<tr>
<td></td>
<td>AATGAGCTGGTGCTGACACGTGCTATACGTAGCA</td>
</tr>
<tr>
<td></td>
<td>AATGAGCTGGTGCTGACACGTGCTATACGTAGCA</td>
</tr>
<tr>
<td></td>
<td>TGGGTGGTTCTGTCTAACCCTATCGGTGTTAACCTGAA</td>
</tr>
<tr>
<td></td>
<td>TGGGTGGTTCTGTCTAACCCTATCGGTGTTAACCTGAA</td>
</tr>
<tr>
<td></td>
<td>ACTGTGGTACCCGTGCTCTGACACGTGCTTTCTGAAACAG</td>
</tr>
<tr>
<td></td>
<td>ACTGTGGTACCCGTGCTCTGACACGTGCTTTCTGAAACAG</td>
</tr>
<tr>
<td></td>
<td>ATGACTACGTGATCTGATGACCCCTGGAATGACGCGTGGT</td>
</tr>
<tr>
<td></td>
<td>ATGACTACGTGATCTGATGACCCCTGGAATGACGCGTGGT</td>
</tr>
<tr>
<td></td>
<td>GGCCGTGACGCTCTGTATG</td>
</tr>
<tr>
<td></td>
<td>GGCCGTGACGCTCTGTATG</td>
</tr>
</tbody>
</table>
Appendix 11 Sequencing Results of IPP in pUC-link

<table>
<thead>
<tr>
<th>IPP Predicted</th>
<th>GGATCCATGGCTAGCATGGGTGTTCTGTCTAAACGT</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPP Actual</td>
<td>GGATCCATGGCTAGCATGGGTGTTCTGTCTAAACGT</td>
</tr>
<tr>
<td></td>
<td>TCGGTTACCTGAAAAAATCTGGGTAAGGTTACGCTG</td>
</tr>
<tr>
<td></td>
<td>TCGGTTACCTGAAAAAATCTGGGTAAGGTTACGCTG</td>
</tr>
<tr>
<td></td>
<td>CGCTGTTCCTGAAAAACAGATGACTAGCATGGGTG</td>
</tr>
<tr>
<td></td>
<td>CGCTGTTCCTGAAAAACAGATGACTAGCATGGGTG</td>
</tr>
<tr>
<td></td>
<td>CTAACGTTATCGGTTACCTGAAAAAATCTGGGTAAGG</td>
</tr>
<tr>
<td></td>
<td>CTAACGTTATCGGTTACCTGAAAAAATCTGGGTAAGG</td>
</tr>
<tr>
<td></td>
<td>GCTCTGAACGCTTTCTGAAAAACAGATGACTAGCATG</td>
</tr>
<tr>
<td></td>
<td>GCTCTGAACGCTTTCTGAAAAACAGATGACTAGCATG</td>
</tr>
<tr>
<td></td>
<td>CCTGCGTGAGATGCTCCTCTAGAGGATCCCCGAGT</td>
</tr>
<tr>
<td></td>
<td>CCTGCGTGAGATGCTCCTCTAGAGGATCCCCGAGT</td>
</tr>
<tr>
<td></td>
<td>TGACTAGTGGGATCTCTCTAGAGGATCCCCGAGT</td>
</tr>
<tr>
<td></td>
<td>TGACTAGTGGGATCTCTCTAGAGGATCCCCGAGT</td>
</tr>
</tbody>
</table>
Appendix 12 Sequencing Results of PGQ3 in pUC-link

PGQ 3 Predicted  GATCCATGGCTAGCATGGGTGTTCTGTCTAACTGTT
                        ****************************************************
PGQ 3 Actual  GATCCATGGCTAGCATGGGTGTTCTGTCTAACTGTT
                          ATCGGTATTACCTGAAAAACTGGGTACCGGTGCTCT
                          ******************************************************
                          ATCGGTATTACCTGAAAAACTGGGTACCGGTGCTCT
GAAACGCTGTTTCTGAAAAACAGATGACTAGCATGGGTG
                        ******************************************************
GAAACGCTGTTTCTGAAAAACAGATGACTAGCATGGGTG
                          TTCTGTCTAACGTTTATCGGTACCTGAAAAACTGGG
                          ******************************************************
                          TTCTGTCTAACGTTTATCGGTACCTGAAAAACTGGG
GTACCGGTGCTCTGAAAAACAGATGACTTAGCATGGGTG
                        ******************************************************
GTACCGGTGCTCTGAAAAACAGATGACTTAGCATGGGTG
                          ACTAGCATGGGTGTTTCTGTCTAACTGTTATCGGTAC
                          ******************************************************
                          ACTAGCATGGGTGTTTCTGTCTAACTGTTATCGGTAC
CTGAAAAACTGGAACCGGTGCTCTGAAAAACATGGTT
                        ******************************************************
CTGAAAAACTGGAACCGGTGCTCTGAAAAACATGGTT
                          CTGAAAAACAGATGACTAGTGG
                          ******************************************************
                          CTGAAAAACAGATGACTAGTGG

80
Appendix 13 Sequencing Results of PGQ6 in pUC-link

PGQ 6 Predicted  GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTT

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

PGQ 6 Actual  GGATCCATGGCTAGCATGGGTGTTCTGTCTAACGTT

ATCGGTTACCTGAAAAACTGGGTACCAGTGCTCTTG

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

ATCGGTTACCTGAAAAACTGGGTACCAGTGCTCTTG

AACGCTGTTCGTTACAAACAGATGACTAGCATGGGTGTT

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

AACGCTGTTCGTTACAAACAGATGACTAGCATGGGTGTT

CTGTCTAAACGTTCGTTACATTGAAAAACTGGGTA

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

CTGTCTAAACGTTCGTTACATTGAAAAACTGGGTA

CGGGTGCTCTGAACGCTGTTCTGAAACAGATGACTA

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

CGGGTGCTCTGAACGCTGTTCTGAAACAGATGACTA

GCATGGGTGTTCTGTTCTAAACGTTCGTTACCTGAA

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

GCATGGGTGTTCTGTTCTAAACGTTCGTTACCTGAA

AAAACGTTACCCGTTGCTCTGAAAAACGCTTCTGAA

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

AAAACGTTACCCGTTGCTCTGAAAAACGCTTCTGAA

ACAGATGACTAGCATTGGTGGTTCTGTCTAACCCTAT

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

ACAGATGACTAGCATTGGTGGTTCTGTCTAACCCTAT

GGTTACCTGAAAAACTGGGTACCGTGCTCTGAACCG

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

GGTTACCTGAAAAACTGGGTACCGTGCTCTGAACCG

CTGTCTGGAAAAACAGATGACTAGCATGGGTGTTCTG

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

CTGTCTGGAAAAACAGATGACTAGCATGGGTGTTCTG

AACGTTATCGGTTACCTGAAAAACTGGGTACCGTG

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

AACGTTATCGGTTACCTGAAAAACTGGGTACCGTG
CTCTGAACGCTGTCTCTGAACACAGATGACTAGCATGGG

CTCTGAACGCTGTCTCTGAACACAGATGACTAGCATGGG

TGTTCTGTCTAAGCTTACGTACCACTGAAAAACTGG

TGTTCTGTCTAAGCTTACGTACCACTGAAAAACTGG

GTACCGGTGCTCTGAAACAGCTTCTCTGAACACAGATGACT

GTACCGGTGCTCTGAAACAGCTTCTCTGAACACAGATGACT

AGTGGAATCC

AGNGGGATCC